Influence of immune privilege on ocular tumor development

Ocular Immunology and Inflammation

Volumn 18, Issue 2, 2010, Pages 80-90

  McKenna, Kyle C ^a   Chen, Peter W ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CD8; CTL; Epigenetic; Immune privilege; Macrophage; T cells; Tumor

Indexed keywords

ALPHA INTERMEDIN; CALCITONIN GENE RELATED PEPTIDE; GAMMA INTERFERON; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; EPIGENETICS; EYE TUMOR; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPIGENESIS, GENETIC; EYE; EYE NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; MACROPHAGES; MELANOMA; MICE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 77950587856     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273941003669950     Document Type: Review

References (110)

1. Streilein JW. Ocular immune privilege: Therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3:879-889.
2. Niederkorn JY. See no evil, hear no evil, do no evil: The lessons of immune privilege. Nat Immunol. 2006;7:354-359.
3. Niederkorn JY, Shadduck JA, Streilein JW. Immunogenetic basis for immunologic privilege in the anterior chamber of the eye. Immunogenetics. 1981;13:227-236.
4. Niederkorn JY, Streilein JW. Analysis of antibody production induced by allogeneic tumor cells inoculated into the anterior chamber of the eye. Transplantation. 1982;33:573-577.
5. Niederkorn JY, Streilein JW. Intracamerally induced concomitant immunity: Mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J Immunol. 1983;131:2587-2594.
6. McKenna KC, Kapp JA. Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. J Immunol. 2006;177:1599-1608.
7. Niederkorn JY, Streilein JW. Adoptive transfer of immunity to intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1984;25:336-342.
8. Bill A. Basic physiology of the drainage of aqueous humor. Exp Eye Res. 1977;25 Suppl:291-304. (Pubitemid 8205041)
9. Schroedl F, Brehmer A, Neuhuber WL, Kruse FE, May CA, Cursiefen C. The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. Invest Ophthalmol Vis Sci. 2008;49:5222-5229.
10. Patel SP, Dana R. Corneal lymphangiogenesis: Implications in immunity. Semin Ophthalmol. 2009;24:135-138.
11. Crane IJ, Liversidge J. Mechanisms of leukocyte migration across the blood-retina barrier. Semin Immunopathol. 2008;30:165-177.
12. Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Woodward JG. Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site. J Immunol. 1996;157:2262-2271.
13. Perez VL, Biuckians AJ, Streilein JW. In-vivo impaired T helper 1 cell development in submandibular lymph nodes due to IL-12 deficiency following antigen injection into the anterior chamber of the eye. Ocul Immunol Inflamm. 2000;8:9-24.
14. McKenna KC, Xu Y, Kapp JA. Injection of soluble antigen into the anterior chamber of the eye induces expansion and functional unresponsiveness of antigen-specific CD8+ T cells. J Immunol. 2002;169:5630-5637.
15. Bill A. Aqueous humor dynamics in monkeys (Macaca irus and Cercopithecus ethiops). Exp Eye Res. 1971;11:195-206.
16. Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ. Requirements for passage of T lymphocytes across non-inflamed retinal microvessels. J Neuroimmunol. 2003;142:47-57.
17. Abi-Hanna D, Wakefield D, Watkins S. HLA antigens in ocular tissues. I. In vivo expression in human eyes. Transplantation. 1988;45:610-613.
18. Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Invest Ophthalmol Vis Sci. 2004;45:3185-3195.
19. Radosevich M, Jager M, Ono SJ. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator. Exp Mol Pathol. 2007;82:68-76.
20. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol Allergy. 2007;92:71-85.
21. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigenpresenting cells. J Immunol. 1998;160:1589-1597.
22. Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells. Int Immunol. 2006;18:689-699.
23. Taylor AW, Alard P, Yee DG, Streilein JW. Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells. Curr Eye Res. 1997;16:900-908.
24. Kezuka T, Streilein JW. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci. 2000;41:1803-1811.
25. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol. 2002;72:946-952.
26. Nishida T, Taylor AW. Specific aqueous humor factors induce activation of regulatory T cells. Invest Ophthalmol Vis Sci. 1999;40:2268-2274.
27. Taylor AW, Yee DG. Somatostatin is an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 2003;44:2644-2649.
28. Sugita S. Role of ocular pigment epithelial cells in immune privilege. Arch Immunol Ther Exp (Warsz). 2009;57:263-268.
29. Sugita S, Usui Y, Horie S, Futagami Y, Aburatani H, Okazaki T, Honjo T, Takeuchi M, Mochizuki M. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci. 2009;50:2862-2870.
30. Hori J, Wang M, Miyashita M, Tanemoto K, Takahashi H, Takemori T, Okumura K, Yagita H, Azuma M. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;177:5928-5935.
31. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
32. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
33. Streilein JW, Niederkorn JY, Shadduck JA. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J Exp Med. 1980;152:1121-1125.
34. Streilein JW, Niederkorn JY. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J Immunol. 1985;134:1381-1387.
35. Ksander BR, Streilein JW. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors. Invest Ophthalmol Vis Sci. 1989;30:323-329.
36. Streilein JW, Niederkorn JY. Induction of anterior chamberassociated immune deviation requires an intact, functional spleen. J Exp Med. 1981;153:1058-1067.
37. Niederkorn JY. Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res. 2009;28:329-347.
38. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:956-961. (Pubitemid 36560496)
39. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3-9.
40. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682.
41. Lee HO, Herndon JM, Barreiro R, Griffith TS, Ferguson TA. TRAIL: A mechanism of tumor surveillance in an immune privileged site. J Immunol. 2002;169:4739-4744.
42. Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 2004;64:6775-6782.
43. Poulaki V, Mitsiades CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, Halikias IX, Voutsinas G, Tseleni-Balafouta S, Miller JW, Mitsiades N. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: Role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci. 2005;46:358-366.
44. Ehrlich P. Ueber den Jetzigen Stand der Karzinom, Forschung. Ned Tijdschr Geneesk. 1909;53:273-298.
45. Thomas LM, Hardy WG, Lindner DW, Gurdjian ES. Cranioplasty with special reference to the repair of large defects with methylmethacrylate. Grace Hosp Bul. 1959;37:55-62.
46. Old LJ, Boyse EA. Specific antigens of tumors and leukemias of experimental animals. Med Clin North Am. 1966;50:901-912.
47. Klein G. Tumor antigens. Annu Rev Microbiol. 1966;20:223-252.
48. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1-50.
49. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: An equilibrium with cancer. J Leukoc Biol. 2008;84:988-993.
50. Block MS, Markovic SN. The tumor/immune interface: Clinical evidence of cancer immunosurveillance, immunoediting, and immunosubversion. Am J Immunol. 2009;5:29-49.
51. Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother. 2009;58:653-664.
52. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008;14:3372-3379.
53. Li XL, Liu YY, Knight D, Odaka Y, Mathis JM, Shi R, Glass J, Zhang QJ. Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression. PLoS ONE. 2009;4:e6385.
54. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005.
55. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest. 1996;98:1633-1641.
56. Méndez R, Ruiz-Cabello F, Rodríguez T, Del Campo A, Paschen A, Schadendorf D, Garrido F. Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother. 2007;56:88-94.
57. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res. 1996;2:1383-1390.
58. Bartlett JM, Langdon SP, Scott WN, Love SB, Miller EP, Katsaros D, Smyth JF, Miller WR. Transforming growth factorbeta isoform expression in human ovarian tumours. Eur J Cancer. 1997;33:2397-2403.
59. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res. 1989;49:6972-6975.
60. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science. 1996;274:1363-1366. (Pubitemid 26391458)
61. Li H, Fan X, Stoicov C, Liu JH, Zubair S, Tsai E, Ste Marie R, Wang TC, Lyle S, Kurt-Jones E, Houghton J. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology. 2009;137:934-944.
62. Hori J, Joyce N, Streilein JW. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest Ophthalmol Vis Sci. 2000;41:443-452. (Pubitemid 30080447)
63. Hori J, Joyce NC, Streilein JW. Immune privilege and immunogenicity reside among different layers of the mouse cornea. Invest Ophthalmol Vis Sci. 2000;41:3032-3042.
64. Talmage DW. Single point mutation or chromosomal rearrangement. Science. 1965; 150:1484-1485.
65. Prendergast GC, Cole MD. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Mol Cell Biol. 1989;9:124-134.
66. Patel MS, Harris RA. Mammalian alpha-keto acid dehydrogenase complexes: Gene regulation and genetic defects. FASEB J. 1995;9:1164-1172.
67. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancerderived mutation. J Biol Chem. 2001;276:14537-14540. (Pubitemid 37373320)
68. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
69. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:5230-5234.
70. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599-602.
71. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301:89-92. (Pubitemid 13154475)
72. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, Mao JH, Balmain A, Cano A, Esteller M. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004;64:5527-5534. (Pubitemid 39095543)
73. Iacobuzio-Donahue CA. Epigenetic changes in cancer. Annu Rev Pathol. 2009;4:229-249.
74. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455. (Pubitemid 36444319)
75. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8:286-298. (Pubitemid 46439286)
76. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet. 1991;48:880-888. (Pubitemid 21891632)
77. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686-692.
78. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D. Regulation of p53 activity through lysine methylation. Nature. 2004;432:353-360. (Pubitemid 39551664)
79. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323-5335. (Pubitemid 37279943)
80. Bird AP, Wolffe AP. Methylation-induced repression--belts, braces, and chromatin. Cell. 1999;99:451-454.
81. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992;69:915-926.
82. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 2000;24:88-91.
83. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene. 1993;8:1063-1067. (Pubitemid 23087441)
84. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986;321:209-213.
85. Aoki A, Suetake I, Miyagawa J, Fujio T, Chijiwa T, Sasaki H, Tajima S. Enzymatic properties of de novo-type mouse DNA (cytosine-5) methyltransferases. Nucleic Acids Res. 2001;29:3506-3512. (Pubitemid 32898764)
86. Kiekhaefer CM, Grass JA, Johnson KD, Boyer ME, Bresnick EH. Hematopoietic-specific activators establish an overlapping pattern of histone acetylation and methylation within a mammalian chromatin domain. Proc Natl Acad Sci USA. 2002;99:14309-14314.
87. Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA, van der Velden PA. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:1291-1298.
88. Holling TM, Bergevoet MW, Wilson L, Van Eggermond MC, Schooten E, Steenbergen RD, Snijders PJ, Jager MJ, Van den Elsen PJ. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol. 2007;179:5317-5325.
89. Chen PW, Uno T, Ksander BR. Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection. J Immunol. 2006;177:162-168. (Pubitemid 43939128)
90. Boonman ZF, van Mierlo GJ, Fransen MF, de Keizer RJ, Jager MJ, Melief CJ, Toes RE. Maintenance of immune tolerance depends on normal tissue homeostasis. J Immunol. 2005;175:4247-4254.
91. Kan-Mitchell J, Liggett PE, Harel W, Steinman L, Nitta T, Oksenberg JR, Posner MR, Mitchell MS. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol Immunother. 1991;33:333-340.
92. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, Murray TG. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. Curr Eye Res. 1998;17:165-173. (Pubitemid 28073782)
93. Niederkorn JY. Suppressed cellular immunity in mice harboring intraocular melanomas. Invest Ophthalmol Vis Sci. 1984;25:447-454.
94. Ksander BR, Streilein JW. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J Immunol. 1990;145:2057-2063.
95. McKenna KC, Beatty KM, Bilonick RA, Schoenfield L, Lathrop KL, Singh AD. Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma. Invest Ophthalmol Vis Sci. 2009;50:4295-4303.
96. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
97. Niederkorn JY, Meunier PC. Spontaneous immune rejection of intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1985;26:877-884. (Pubitemid 15063881)
98. Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol. 1987;138:4515-4523.
99. Niederkorn JY, Knisely TL. Immunological analysis of a destructive pattern of intraocular tumor resolution. Curr Eye Res. 1988;7:515-526.
100. Niederkorn JY, Benson JL, Mayhew E. Efferent blockade of delayed-type hypersensitivity responses in the anterior chamber of the eye. Reg Immunol. 1990;3:349-354.
101. Schurmans LR, Diehl L, den Boer AT, Sutmuller RP, Boonman ZF, Medema JP, van der Voort EI, Laman J, Melief CJ, Jager MJ, Toes RE. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis. J Immunol. 2001;167:5832-5837. (Pubitemid 33062775)
102. Wang S, Boonman ZF, Li HC, He Y, Jager MJ, Toes RE, Niederkorn JY. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol. 2003;171:2789-2796. (Pubitemid 37093497)
103. Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, Jager MJ. Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci. 2006;47:2959-2965. (Pubitemid 351639772)
104. Dace DS, Chen PW, Niederkorn JY. CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology. 2008;123:367-377.
105. Dace DS, Chen PW, Niederkorn JY. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism. J Immunol. 2007;178:6115-6122.
106. Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol. 2004;173:1738-1743. (Pubitemid 38971605)
107. Hollenbaugh JA, Dutton RW. IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol. 2006;177:3004-3011.
108. Taylor AW, Yee DG, Streilein JW. Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor. Invest Ophthalmol Vis Sci. 1998;39:1372-1378.
109. Blanckaert VD, Schelling ME, Elstad CA, Meadows GG. Differential growth factor production, secretion and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res. 1993;53:4075-4081.
110. Ma D, Alizadeh H, Comerford SA, Gething MJ, Sambrook JF, Anand R, Niederkorn JY. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res. 1994;13:361-369. (Pubitemid 24148118)